Hormone Replacement Therapy and Cardioprotection

Philip M. Sarrel, Giuseppe M C Rosano

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Estrogen deficiency plays a key role in causing the development of cardiovascular disease (CVD) in women. Ovarian hormones have protective effects on cardiovascular risk factors and functions. This chapter summarizes the clinical studies and the studies of ovarian actions affecting cardiovascular functions to determine the significance of these actions. The overall effect of estrogen-progestin therapy on the cardiovascular system is the result of the interaction between estrogens and progestins used in hormone replacement therapy (HRT) schemes. The choice of the correct progestin is crucial to maximize the beneficial effect of estrogens. As far as cardioprotection is concerned, less androgenic progestins should be preferred. Based on a large number of nonrandomized observational studies, there is an average of 35% risk reduction of coronary artery diseasein postmenopausal women using HRT for primary prevention. The absence of benefit for secondary prevention, reported in a single randomized study, is insufficient to draw any conclusions about recommendations for HRT use with respect to cardiovascular protection or harm.

Original languageEnglish
Title of host publicationPrinciples of Gender-Specific Medicine
PublisherElsevier Inc.
Pages255-262
Number of pages8
Volume1
ISBN (Print)9780124409057
DOIs
Publication statusPublished - 2004

Fingerprint

Hormone Replacement Therapy
Progestins
Estrogens
Hormones
Cardiovascular system
Risk Reduction Behavior
Primary Prevention
Cardiovascular System
Secondary Prevention
Observational Studies
Coronary Vessels
Cardiovascular Diseases
Therapeutics

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Sarrel, P. M., & Rosano, G. M. C. (2004). Hormone Replacement Therapy and Cardioprotection. In Principles of Gender-Specific Medicine (Vol. 1, pp. 255-262). Elsevier Inc.. https://doi.org/10.1016/B978-012440905-7/50291-7

Hormone Replacement Therapy and Cardioprotection. / Sarrel, Philip M.; Rosano, Giuseppe M C.

Principles of Gender-Specific Medicine. Vol. 1 Elsevier Inc., 2004. p. 255-262.

Research output: Chapter in Book/Report/Conference proceedingChapter

Sarrel, PM & Rosano, GMC 2004, Hormone Replacement Therapy and Cardioprotection. in Principles of Gender-Specific Medicine. vol. 1, Elsevier Inc., pp. 255-262. https://doi.org/10.1016/B978-012440905-7/50291-7
Sarrel PM, Rosano GMC. Hormone Replacement Therapy and Cardioprotection. In Principles of Gender-Specific Medicine. Vol. 1. Elsevier Inc. 2004. p. 255-262 https://doi.org/10.1016/B978-012440905-7/50291-7
Sarrel, Philip M. ; Rosano, Giuseppe M C. / Hormone Replacement Therapy and Cardioprotection. Principles of Gender-Specific Medicine. Vol. 1 Elsevier Inc., 2004. pp. 255-262
@inbook{3ab48bd07fe7454bb06fcf80df03fe24,
title = "Hormone Replacement Therapy and Cardioprotection",
abstract = "Estrogen deficiency plays a key role in causing the development of cardiovascular disease (CVD) in women. Ovarian hormones have protective effects on cardiovascular risk factors and functions. This chapter summarizes the clinical studies and the studies of ovarian actions affecting cardiovascular functions to determine the significance of these actions. The overall effect of estrogen-progestin therapy on the cardiovascular system is the result of the interaction between estrogens and progestins used in hormone replacement therapy (HRT) schemes. The choice of the correct progestin is crucial to maximize the beneficial effect of estrogens. As far as cardioprotection is concerned, less androgenic progestins should be preferred. Based on a large number of nonrandomized observational studies, there is an average of 35{\%} risk reduction of coronary artery diseasein postmenopausal women using HRT for primary prevention. The absence of benefit for secondary prevention, reported in a single randomized study, is insufficient to draw any conclusions about recommendations for HRT use with respect to cardiovascular protection or harm.",
author = "Sarrel, {Philip M.} and Rosano, {Giuseppe M C}",
year = "2004",
doi = "10.1016/B978-012440905-7/50291-7",
language = "English",
isbn = "9780124409057",
volume = "1",
pages = "255--262",
booktitle = "Principles of Gender-Specific Medicine",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Hormone Replacement Therapy and Cardioprotection

AU - Sarrel, Philip M.

AU - Rosano, Giuseppe M C

PY - 2004

Y1 - 2004

N2 - Estrogen deficiency plays a key role in causing the development of cardiovascular disease (CVD) in women. Ovarian hormones have protective effects on cardiovascular risk factors and functions. This chapter summarizes the clinical studies and the studies of ovarian actions affecting cardiovascular functions to determine the significance of these actions. The overall effect of estrogen-progestin therapy on the cardiovascular system is the result of the interaction between estrogens and progestins used in hormone replacement therapy (HRT) schemes. The choice of the correct progestin is crucial to maximize the beneficial effect of estrogens. As far as cardioprotection is concerned, less androgenic progestins should be preferred. Based on a large number of nonrandomized observational studies, there is an average of 35% risk reduction of coronary artery diseasein postmenopausal women using HRT for primary prevention. The absence of benefit for secondary prevention, reported in a single randomized study, is insufficient to draw any conclusions about recommendations for HRT use with respect to cardiovascular protection or harm.

AB - Estrogen deficiency plays a key role in causing the development of cardiovascular disease (CVD) in women. Ovarian hormones have protective effects on cardiovascular risk factors and functions. This chapter summarizes the clinical studies and the studies of ovarian actions affecting cardiovascular functions to determine the significance of these actions. The overall effect of estrogen-progestin therapy on the cardiovascular system is the result of the interaction between estrogens and progestins used in hormone replacement therapy (HRT) schemes. The choice of the correct progestin is crucial to maximize the beneficial effect of estrogens. As far as cardioprotection is concerned, less androgenic progestins should be preferred. Based on a large number of nonrandomized observational studies, there is an average of 35% risk reduction of coronary artery diseasein postmenopausal women using HRT for primary prevention. The absence of benefit for secondary prevention, reported in a single randomized study, is insufficient to draw any conclusions about recommendations for HRT use with respect to cardiovascular protection or harm.

UR - http://www.scopus.com/inward/record.url?scp=84902042146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902042146&partnerID=8YFLogxK

U2 - 10.1016/B978-012440905-7/50291-7

DO - 10.1016/B978-012440905-7/50291-7

M3 - Chapter

AN - SCOPUS:84902042146

SN - 9780124409057

VL - 1

SP - 255

EP - 262

BT - Principles of Gender-Specific Medicine

PB - Elsevier Inc.

ER -